Search Results for "f"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for f. Results 331 to 340 of 864 total matches.

CT Colonography (Virtual Colonoscopy) Revisited

   
The Medical Letter on Drugs and Therapeutics • Dec 01, 2008  (Issue 1300)
. Roden, M.D., Vanderbilt University School of Medicine F. Estelle R. Simons, M.D., University ...
Options in screening for colon cancer include fecal occult blood tests, flexible sigmoidoscopy, colonoscopy, computed tomography (CT) colonography and fecal DNA tests. Since the last Medical Letter article on this subject, more data have become available on colonography.
Med Lett Drugs Ther. 2008 Dec 1;50(1300):94-5 |  Show IntroductionHide Introduction

CRP and Statins for Primary Prevention of Coronary Artery Disease

   
The Medical Letter on Drugs and Therapeutics • Dec 15, 2008  (Issue 1301)
., University Hospital, Copenhagen Dan M. Roden, M.D., Vanderbilt University School of Medicine F. Estelle R ...
Modestly elevated C-reactive protein (CRP) concentrations have been associated with an increased risk of coronary heart disease. The recently published and heavily publicized results of the JUPITER trial will lead many patients to ask health care professionals whether they should have a CRP test to see if they should be taking a statin.
Med Lett Drugs Ther. 2008 Dec 15;50(1301):97-8 |  Show IntroductionHide Introduction

A Granisetron Patch (Sancuso)

   
The Medical Letter on Drugs and Therapeutics • Dec 15, 2008  (Issue 1301)
School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D., New ...
The treatment of choice to prevent emesis due to highand moderate-risk emetogenic drugs used in cancer chemotherapy is aprepitant plus a serotonin receptor antagonist plus dexamethasone. Four serotonin receptor antagonists are available in the US in intravenous (IV) formulations for prevention of nausea and vomiting due to cancer chemotherapy, and 3 of these are also available for oral use. Now the FDA has approved one of these, granisetron, in a transdermal formulation (Sancuso - ProStrakan).
Med Lett Drugs Ther. 2008 Dec 15;50(1301):103-0 |  Show IntroductionHide Introduction

Dolutegravir (Tivicay) for HIV

   
The Medical Letter on Drugs and Therapeutics • Sep 30, 2013  (Issue 1426)
. F Raffi et al. Lancet 2013; 381:735. 2. S Walmsley et al. Presented at 52nd Interscience Conference ...
The FDA has approved dolutegravir (doll-you-TEG-rah-veer; Tivicay – Viiv Healthcare), an integrase strand transfer inhibitor (INSTI), for treatment of HIV-1 infection in adults and in children ≥12 years old who weigh at least 40 kg. It is the third INSTI to be approved by the FDA; raltegravir and elvitegravir were approved earlier.
Med Lett Drugs Ther. 2013 Sep 30;55(1426):77-9 |  Show IntroductionHide Introduction

An Imaging Agent for Amyloid

   
The Medical Letter on Drugs and Therapeutics • Jul 09, 2012  (Issue 1394)
of amyloid deposition in Alzheimer disease using radioligand 18F-AV-45 (florbetapir F 18). J Nucl Med 2010 ...
The FDA has approved florbetapir F18 (flor bay´ ta pir; Amyvid – Lilly), an intravenous radioactive diagnostic agent used with positron emission tomography (PET) scans, to estimate β-amyloid neuritic plaque density in adults being evaluated for Alzheimer's disease (AD) or other causes of cognitive decline.
Med Lett Drugs Ther. 2012 Jul 9;54(1394):54-5 |  Show IntroductionHide Introduction

Drug Interaction: Dabigatran (Pradaxa) and Statins

   
The Medical Letter on Drugs and Therapeutics • Jan 30, 2017  (Issue 1513)
, atenolol, celecoxib and cimetidine. Int J Clin Pharmacol Ther 2005; 43:527. 7. F Violi et al. Statins ...
The results of a recently published study suggest that taking the oral direct thrombin inhibitor dabigatran etexilate (Pradaxa) with either simvastatin (Zocor, and others) or lovastatin (Altoprev, and others) increases the risk of major hemorrhage.
Med Lett Drugs Ther. 2017 Jan 30;59(1513):26 |  Show IntroductionHide Introduction

In Brief: Expanded Indication for Elevidys

   
The Medical Letter on Drugs and Therapeutics • Aug 19, 2024  (Issue 1709)
. Med Lett Drugs Ther 2023; 65:159. 2. F Muntoni et al. ENVISION, a phase 3, randomized trial ...
The adeno-associated virus (AAV) vector-based gene therapy delandistrogene moxeparvovec-rokl (Elevidys – Sarepta) received accelerated approval from the FDA in 2023 for treatment of ambulatory children 4-5 years old with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the DMD gene. It has now received full approval for use in ambulatory patients ≥4 years old and accelerated approval for use in nonambulatory patients with DMD.
Med Lett Drugs Ther. 2024 Aug 19;66(1709):135-6   doi:10.58347/tml.2024.1709e |  Show IntroductionHide Introduction

Substituting For Troglitazone

   
The Medical Letter on Drugs and Therapeutics • Apr 17, 2000  (Issue 1076)
of Medicine; F. Estelle R. Simons, M.D., University of Manitoba EDITORIAL FELLOWS: Richard Kim, M.D ...
Full-page advertisements in newspapers are urging patients with type 2 diabetes coming off Rezulin to ask their doctors to switch to Avandia or Actos. Troglitazone was withdrawn from the market on March 21 because of rare but severe hepatic toxicity.
Med Lett Drugs Ther. 2000 Apr 17;42(1076):36 |  Show IntroductionHide Introduction

Cosmetic Phalloplasty

   
The Medical Letter on Drugs and Therapeutics • May 24, 2004  (Issue 1183)
, M.D., University Hospital, Copenhagen; Dan M. Roden, M.D., Vanderbilt School of Medicine; F. Estelle ...
Some patients may be asking healthcare providers about the surgical techniques to enlarge the penis that are widely promoted on the Internet. Phalloplasty was first used to treat traumatic or surgical amputation (for cancer), epispadias and Peyronie's disease (JP Yurkanin et al, J Urol 2001; 166:1769).
Med Lett Drugs Ther. 2004 May 24;46(1183):44 |  Show IntroductionHide Introduction

Pantroprazole (Protonix)

   
The Medical Letter on Drugs and Therapeutics • Jul 24, 2000  (Issue 1083)
., University Hospital, Copenhagen; Dan M. Roden, M.D., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D ...
Pantoprazole, the fourth benzimidazole proton pump inhibitor to become available in the United States, has been marketed for short-term oral treatment of erosive gastroesophageal reflux disease (GERD).
Med Lett Drugs Ther. 2000 Jul 24;42(1083):65-6 |  Show IntroductionHide Introduction